Antimalarials in a New Light: The Science Behind Chloroquine's Promise for Lupus, Rheumatoid Arthritis, and Beyond

From Tropical Medicine to Rheumatology Clinics

For most of the twentieth century, chloroquine occupied a narrow but vital role in global health: suppressing and treating malaria caused by Plasmodium species. Yet decades of clinical observation have revealed a secondary dimension to this compound — one that has proven remarkably relevant to millions of Americans living with chronic autoimmune conditions. Today, hydroxychloroquine (HCQ), a less toxic derivative of chloroquine, is among the most frequently prescribed drugs in American rheumatology practices, appearing in treatment regimens for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and several other immune-mediated disorders.

Understanding how a drug designed to combat a parasite became a mainstay of autoimmune therapy requires a closer look at the underlying biology — and at the evolving body of evidence that continues to reshape clinical practice in the United States.

The Pharmacological Case: Why These Drugs Affect the Immune System

Chloroquine and hydroxychloroquine belong to the 4-aminoquinoline class of compounds. Their antimalarial action stems primarily from their ability to accumulate in acidic intracellular compartments, interfering with the parasite's ability to detoxify heme. However, this same affinity for acidic vesicles — specifically lysosomes and endosomes — has profound consequences for human immune cells as well.

Within immune cells, these drugs impair the processing of antigens by elevating lysosomal pH. This disrupts the presentation of self-antigens to autoreactive T cells, a key step in the cascade that drives autoimmune inflammation. Additionally, both chloroquine and HCQ inhibit Toll-like receptors (TLRs), particularly TLR7 and TLR9, which recognize nucleic acid fragments. In diseases like SLE, where aberrant immune responses to nuclear material are central to pathology, this TLR inhibition translates into meaningful reductions in interferon-alpha production and downstream inflammatory signaling.

The net effect is a modulation — rather than wholesale suppression — of immune activity. This nuanced action distinguishes antimalarials from more aggressive immunosuppressants and contributes to their relatively favorable safety profile when used at appropriate doses.

What the Evidence Says: Lupus and Rheumatoid Arthritis

The evidence base for hydroxychloroquine in SLE is among the most robust in rheumatology. Landmark studies, including the Canadian Hydroxychloroquine Study Group trial, demonstrated that discontinuing HCQ in lupus patients led to significantly higher rates of disease flares. Current guidelines from the American College of Rheumatology (ACR) recommend HCQ for virtually all patients with SLE who can tolerate it, citing benefits that extend from symptom control to reduced organ damage accrual and even improved survival over time.

In rheumatoid arthritis, HCQ occupies a specific niche. It is classified as a conventional synthetic disease-modifying antirheumatic drug (csDMARD) and is frequently used as part of combination regimens — most notably the "triple therapy" protocol pairing HCQ with methotrexate and sulfasalazine. Clinical trials have shown this combination to be comparable in efficacy to biologic therapies for certain RA populations, offering a cost-effective alternative for patients who may face barriers to biologic access.

Research interest has also extended to other conditions. Investigators have examined HCQ's role in primary Sjögren's syndrome, antiphospholipid syndrome, dermatomyositis, and even certain presentations of undifferentiated connective tissue disease. While the evidence in these areas remains less definitive, ongoing trials continue to generate data that may refine prescribing guidance in the coming years.

Active Clinical Trials and Emerging Research Directions

As of the mid-2020s, ClinicalTrials.gov lists multiple active and recruiting studies evaluating HCQ and chloroquine across autoimmune indications. Several trials are investigating whether HCQ can delay the progression from early or undifferentiated autoimmune disease to established diagnoses such as SLE or RA — a concept sometimes called "preventive rheumatology."

Additionally, researchers are exploring HCQ's potential cardioprotective and metabolic benefits in autoimmune populations. Studies have observed lower rates of thrombotic events and improved lipid profiles in SLE patients on long-term HCQ therapy, prompting interest in whether these effects are pharmacologically mediated or secondary to better disease control. Answers to these questions could meaningfully expand the drug's value proposition in managing complex, multi-system autoimmune disease.

Navigating Off-Label Use: What Patients and Providers Should Understand

While HCQ carries FDA approval for lupus and RA, its application in other autoimmune conditions is considered off-label. This distinction carries practical implications. Patients and clinicians should be aware that off-label prescribing is both legal and common in American medicine, but it may affect insurance coverage decisions.

Many commercial insurers and Medicare plans cover HCQ for lupus and RA with appropriate documentation. However, coverage for off-label indications can require prior authorization, detailed clinical justification, or appeals. Patients encountering coverage denials are encouraged to work with their rheumatologist to submit supporting clinical literature and, where applicable, explore patient assistance programs offered by manufacturers.

Safety Monitoring: The Retinal Risk and Beyond

No discussion of long-term HCQ therapy is complete without addressing retinal toxicity — the most serious adverse effect associated with prolonged use. Hydroxychloroquine can accumulate in retinal pigment epithelium, causing a characteristic pattern of maculopathy that, if undetected, may lead to permanent vision loss. The risk is dose-dependent and increases substantially after five or more years of continuous therapy.

The ACR and the American Academy of Ophthalmology (AAO) both recommend baseline ophthalmologic evaluation before or shortly after initiating therapy, followed by annual screening after five years of use — or earlier in patients with pre-existing renal impairment, high cumulative doses, or other risk factors. Modern screening tools, including spectral-domain optical coherence tomography (SD-OCT) and multifocal electroretinography, have significantly improved early detection capabilities.

Other safety considerations include QT interval prolongation (particularly relevant when HCQ is co-administered with other medications affecting cardiac conduction), gastrointestinal intolerance, and, less commonly, neuropsychiatric effects. Routine monitoring of renal function is also advisable, as the drug is renally cleared and dose adjustments may be warranted in patients with chronic kidney disease.

A Balanced Perspective for the American Healthcare Landscape

For patients in the United States living with autoimmune disease, hydroxychloroquine represents a therapeutically versatile, generally well-tolerated option with a decades-long track record. Its relatively low cost compared to biologic agents, combined with its multi-system benefits in diseases like lupus, has secured its place as a foundational therapy in rheumatologic care.

That said, appropriate use demands informed prescribing, consistent monitoring, and clear communication between patients and their healthcare teams. As research continues to illuminate new applications and refine dosing strategies, antimalarial compounds are poised to remain central figures in the autoimmune pharmacopeia — far removed from their origins in tropical disease, yet no less essential.